<DOC>
	<DOCNO>NCT00132158</DOCNO>
	<brief_summary>The purpose Phase I study find large dose drug irinotecan , combination ZD1839 , give safely child learn good bad effect . Studies perform laboratory show ZD1839 help make available orally administer irinotecan . In study intravenous ( give vein ) formula irinotecan give orally day 1-5 day 8-12 . The dose ZD1839 fix dose administer orally day 1-12 . Each course treatment consist 21 day . The administration irinotecan day 12 course 1 day 2 course 2 intravenous administration . All dose subsequent course consist orally administer dose .</brief_summary>
	<brief_title>ZD1839 Oral Irinotecan Treating Young Patients With Refractory Solid Tumors</brief_title>
	<detailed_description>This phase I study estimate maximum tolerate dose dose limit toxicity intravenous formulation irinotecan give orally combination fix dose oral gefitinib . This trial use EWOC method , adaptive dose escalation scheme . The method fully adaptive make use information available time dose assignment , directly address ethical need control probability overdose . It design approach maximum tolerate dose ( MTD ) fast possible . In study intravenous formulation irinotecan give orally day 1-5 day 8-12 ( dose level begin 5 mg/m2 ) . One patient treat dose level irinotecan moderate toxicity observe . At level moderate toxicity observe , cohort size increase 2 patient . Dosages increase development DLT guide EWOC model . The estimated MTD continually reassess use data precede patient . The toxicity data patient enrol trial use update dose-toxicity relationship guide next escalation/de-escalation . The calculation carry EWOC software . Patients enrol dose assign determine base previous participant ' toxicity . The dose ZD1839 fix dose administer orally day 1-12 - [ 150 mg/m2 ( maximum 250 mg ) ] Each course treatment consist 21 day . The administration irinotecan day 12 course 1 day 2 course 2 intravenous administration . All dose subsequent course consist orally administer dose . Secondary Objectives Include : - To describe dose-limiting toxicity ( DLTs ) combination oral irinotecan ZD1839 define duration reversibility . - To investigate pharmacokinetics oral irinotecan ZD1839 give combination child recurrent malignant solid tumor . - To describe relationship pharmacokinetic parameter toxicity . - To describe antitumor effect within confines phase I study . - To examine tumor expression ErbB1 and/or ABCG2 respect pharmacokinetics response . - To examine pharmacogenetic determinant ZD1839 irinotecan pharmacokinetics pharmacodynamics .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Patient 's age le equal 21 year time study entry . Patient histologically pathologically confirm diagnosis recurrent solid tumor respond standard treatment one know therapy . Patient adequate performance status , along adequate function liver , kidney bone marrow . Must recover chemotherapy No active GVHD treatment GVHD Patient receive cytotoxic investigational drug evidence another active illness Active diarrhea Active intercurrent serious uncontrolled illness Pregnant lactating Concomitant use medication may interact study drug Active infection Known history lifethreatening allergy hypersensitivity camptothecin Active interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>